Array BioPharma Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares

BOULDER, Colo., Oct. 3, 2016 /PRNewswire/ -- Array BioPharma Inc. (NasdaqGM: ARRY) announced today the closing of its underwritten public offering of 21,160,000 shares of its common stock, which includes 2,760,000 shares of common stock issued upon the exercise in full of the option to purchase additional shares granted to the underwriters, at a public offering price of $6.25 per share. The total gross proceeds from the offering are $132.25 million, before underwriting discounts and commissions and offering expenses. 

J.P. Morgan Securities LLC and Cowen and Company, LLC acted as joint book-running managers for the offering.  Stifel and Wells Fargo Securities, LLC acted as lead managers and SunTrust Robinson Humphrey, Inc. acted as co-manager.

The shares were sold pursuant to an effective shelf registration statement filed with the Securities and Exchange Commission (the "SEC"). This press release does not constitute an offer to sell, or the solicitation of an offer to buy, these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale is not permitted. 

A final prospectus supplement relating to the offering was filed with the SEC and is available on the SEC's web site at www.sec.gov. Copies of the final prospectus supplement and accompanying prospectus may be obtained from either: J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, telephone: 866-803-9204, or Cowen and Company, LLC, c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, New York, 11717, Attn: Prospectus Department, telephone: 631-274-2806.

About Array BioPharma
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. Five registration studies are currently advancing related to three cancer drugs. These programs include binimetinib (MEK162), encorafenib (LGX818) and selumetinib (AstraZeneca).

Logo - http://photos.prnewswire.com/prnh/20121029/LA02195LOGO

SOURCE Array BioPharma

Related Links

http://www.arraybiopharma.com